Neuburgh Advisers’s Cyclerion Therapeutics CYCN Stock Holding History

Neuburgh Advisers’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$11K	Hold	44	–	–	﹤0.01%	904
2019 Q2	$10K	Buy	+44	New	+$12.5K	﹤0.01%	902

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Neuburgh Advisers's CYCN Position: Q3 2019 in Review

Neuburgh Advisers held its Cyclerion Therapeutics (CYCN) position steady in Q3 2019 at 44 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #904.

Neuburgh Advisers first reported a position in CYCN in Q2 2019 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

Neuburgh Advisers held 44 shares of Cyclerion Therapeutics worth $11K as of Q3 2019.
Neuburgh Advisers left its Cyclerion Therapeutics share count unchanged in Q3 2019.
Cyclerion Therapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #904 holding.
Neuburgh Advisers first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 2 quarters since.
90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.